49 related articles for article (PubMed ID: 37752540)
21. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.
Powell SF; Rodríguez-Abreu D; Langer CJ; Tafreshi A; Paz-Ares L; Kopp HG; Rodríguez-Cid J; Kowalski DM; Cheng Y; Kurata T; Awad MM; Lin J; Zhao B; Pietanza MC; Piperdi B; Garassino MC
J Thorac Oncol; 2021 Nov; 16(11):1883-1892. PubMed ID: 34265431
[TBL] [Abstract][Full Text] [Related]
22. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer.
Krishna S; Lowery FJ; Copeland AR; Bahadiroglu E; Mukherjee R; Jia L; Anibal JT; Sachs A; Adebola SO; Gurusamy D; Yu Z; Hill V; Gartner JJ; Li YF; Parkhurst M; Paria B; Kvistborg P; Kelly MC; Goff SL; Altan-Bonnet G; Robbins PF; Rosenberg SA
Science; 2020 Dec; 370(6522):1328-1334. PubMed ID: 33303615
[TBL] [Abstract][Full Text] [Related]
23. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
[TBL] [Abstract][Full Text] [Related]
24. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.
Hong L; Negrao MV; Dibaj SS; Chen R; Reuben A; Bohac JM; Liu X; Skoulidis F; Gay CM; Cascone T; Mitchell KG; Tran HT; Le X; Byers LA; Sepesi B; Altan M; Elamin YY; Fossella FV; Kurie JM; Lu C; Mott FE; Tsao AS; Rinsurongkawong W; Lewis J; Gibbons DL; Glisson BS; Blumenschein GR; Roarty EB; Futreal PA; Wistuba II; Roth JA; Swisher SG; Papadimitrakopoulou VA; Heymach JV; Lee JJ; Simon GR; Zhang J
J Thorac Oncol; 2020 Sep; 15(9):1449-1459. PubMed ID: 32389639
[TBL] [Abstract][Full Text] [Related]
25. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Gadgeel S; Rodríguez-Abreu D; Speranza G; Esteban E; Felip E; Dómine M; Hui R; Hochmair MJ; Clingan P; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Garon EB; Novello S; Rubio-Viqueira B; Boyer M; Kurata T; Gray JE; Yang J; Bas T; Pietanza MC; Garassino MC
J Clin Oncol; 2020 May; 38(14):1505-1517. PubMed ID: 32150489
[TBL] [Abstract][Full Text] [Related]
26. Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy.
Valpione S; Galvani E; Tweedy J; Mundra PA; Banyard A; Middlehurst P; Barry J; Mills S; Salih Z; Weightman J; Gupta A; Gremel G; Baenke F; Dhomen N; Lorigan PC; Marais R
Nat Cancer; 2020 Feb; 1(2):210-221. PubMed ID: 32110781
[TBL] [Abstract][Full Text] [Related]
27. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.
Jansen CS; Prokhnevska N; Master VA; Sanda MG; Carlisle JW; Bilen MA; Cardenas M; Wilkinson S; Lake R; Sowalsky AG; Valanparambil RM; Hudson WH; McGuire D; Melnick K; Khan AI; Kim K; Chang YM; Kim A; Filson CP; Alemozaffar M; Osunkoya AO; Mullane P; Ellis C; Akondy R; Im SJ; Kamphorst AO; Reyes A; Liu Y; Kissick H
Nature; 2019 Dec; 576(7787):465-470. PubMed ID: 31827286
[TBL] [Abstract][Full Text] [Related]
28. TCR Repertoire Diversity of Peripheral PD-1
Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
[TBL] [Abstract][Full Text] [Related]
29. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK; Wu YL; Kudaba I; Kowalski DM; Cho BC; Turna HZ; Castro G; Srimuninnimit V; Laktionov KK; Bondarenko I; Kubota K; Lubiniecki GM; Zhang J; Kush D; Lopes G;
Lancet; 2019 May; 393(10183):1819-1830. PubMed ID: 30955977
[TBL] [Abstract][Full Text] [Related]
31. Subsets of exhausted CD8
Miller BC; Sen DR; Al Abosy R; Bi K; Virkud YV; LaFleur MW; Yates KB; Lako A; Felt K; Naik GS; Manos M; Gjini E; Kuchroo JR; Ishizuka JJ; Collier JL; Griffin GK; Maleri S; Comstock DE; Weiss SA; Brown FD; Panda A; Zimmer MD; Manguso RT; Hodi FS; Rodig SJ; Sharpe AH; Haining WN
Nat Immunol; 2019 Mar; 20(3):326-336. PubMed ID: 30778252
[TBL] [Abstract][Full Text] [Related]
32. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.
Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina JR; Kim JH; Dubos Arvis C; Ahn MJ; Majem M; Fidler MJ; Surmont V; de Castro G; Garrido M; Shentu Y; Emancipator K; Samkari A; Jensen EH; Lubiniecki GM; Garon EB
Ann Oncol; 2019 Feb; 30(2):281-289. PubMed ID: 30657853
[TBL] [Abstract][Full Text] [Related]
33. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
34. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Bray F; Ferlay J; Soerjomataram I; Siegel RL; Torre LA; Jemal A
CA Cancer J Clin; 2018 Nov; 68(6):394-424. PubMed ID: 30207593
[TBL] [Abstract][Full Text] [Related]
35. Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
Manjarrez-Orduño N; Menard LC; Kansal S; Fischer P; Kakrecha B; Jiang C; Cunningham M; Greenawalt D; Patel V; Yang M; Golhar R; Carman JA; Lezhnin S; Dai H; Kayne PS; Suchard SJ; Bernstein SH; Nadler SG
Front Immunol; 2018; 9():1613. PubMed ID: 30123214
[TBL] [Abstract][Full Text] [Related]
36. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Kelsch C; Lee A; Coleman S; Deng Y; Shen Y; Kowanetz M; Lopez-Chavez A; Sandler A; Reck M;
N Engl J Med; 2018 Jun; 378(24):2288-2301. PubMed ID: 29863955
[TBL] [Abstract][Full Text] [Related]
37. Emerging biomarkers for immune checkpoint inhibition in lung cancer.
Cyriac G; Gandhi L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):269-277. PubMed ID: 29782924
[TBL] [Abstract][Full Text] [Related]
38. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.
Kamphorst AO; Pillai RN; Yang S; Nasti TH; Akondy RS; Wieland A; Sica GL; Yu K; Koenig L; Patel NT; Behera M; Wu H; McCausland M; Chen Z; Zhang C; Khuri FR; Owonikoko TK; Ahmed R; Ramalingam SS
Proc Natl Acad Sci U S A; 2017 May; 114(19):4993-4998. PubMed ID: 28446615
[TBL] [Abstract][Full Text] [Related]
39. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.
de Coaña YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nyström M; Edbäck U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
Oncotarget; 2017 Mar; 8(13):21539-21553. PubMed ID: 28423487
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Leiby MA; Lubiniecki GM; Shentu Y; Rangwala R; Brahmer JR;
N Engl J Med; 2016 Nov; 375(19):1823-1833. PubMed ID: 27718847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
